Bildkälla: Stockfoto

Hansa Biopharma: Activates the European confirmation study for Idefirix - Redeye

The news is welcome as the 50-patient European PAES study expands the European reference clinics and the study is also a requirement to advance the conditional European Idefirix approval to unconditional approval.

The news is welcome as the 50-patient European PAES study expands the European reference clinics and the study is also a requirement to advance the conditional European Idefirix approval to unconditional approval.
Börsvärldens nyhetsbrev
ANNONSER